---
title: "BlossomHill reports 45% ORR, 88% DCR for BH-30643 in C797S-positive NSCLC; Phase 2 planned"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299043586.md"
description: "BlossomHill Therapeutics reported interim Phase 1/2 SOLARA trial results for BH-30643 in EGFR C797S-positive NSCLC, showing a 45% objective response rate and 88% disease control rate. The drug demonstrated durability with 63% of patients remaining on treatment at median 6.9 months follow-up and a favorable safety profile. Following FDA Fast Track designation, the company plans to initiate a global Phase 2 study in Q1 2027."
datetime: "2026-09-15T11:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299043586.md)
  - [en](https://longbridge.com/en/news/299043586.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299043586.md)
generator: "portal-rs"
---

# BlossomHill reports 45% ORR, 88% DCR for BH-30643 in C797S-positive NSCLC; Phase 2 planned

**BlossomHill reported a 45% objective response rate and 88% disease control rate for BH-30643 in EGFR C797S-positive NSCLC.**

**Key Highlights:**

-   Phase 1/2 SOLARA update shows 45% ORR (18/40) and 88% DCR (35/40) in C797S-positive patients.
-   63% (25/40) of patients remained on treatment at median 6.9 months follow-up, suggesting durability.
-   Favorable safety: among 174 patients at expansion doses, treatment-related dose reductions 9% and discontinuations 3%.
-   Activity observed in a heavily pretreated, heterogeneous cohort: 98% prior osimertinib; 35% had concurrent T790M.
-   Company received FDA Fast Track for BH-30643 and plans a global Phase 2 in C797S-positive NSCLC in Q1 2027.

Original SEC Filing: BlossomHill Therapeutics, Inc. \[ BLSM \] - 8-K - Sep. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BLSM.US](https://longbridge.com/en/quote/BLSM.US.md)

## Related News & Research

- [BlossomHill Therapeutics advances pan-KRAS inhibitor BH-501284 toward Q1 2027 IND filing after preclinical data presentation](https://longbridge.com/en/news/300292874.md)
- [BlossomHill: Robust Emerging KRAS Franchise and Promising BH-501284 Data Support Unchanged $35 Price Target and Buy Rating](https://longbridge.com/en/news/300461144.md)
- [uniQure says AMT-130 Phase I/II data show 80% slowing on cUHDRS at 36 months in high-dose Huntington’s patients](https://longbridge.com/en/news/300426091.md)
- [Nvidia’s CEO draws Pope Leo’s criticism as AI safety concerns surge 50%](https://longbridge.com/en/news/300379637.md)
- [BlossomHill Therapeutics to present updated Phase 1/2 SOLARA trial data on BH-30643 in EGFR-mutant NSCLC at WCLC 2026](https://longbridge.com/en/news/297641175.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**